|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target.
|
31501192 |
2019 |
|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genomic amplification of the oncogene MYCN is a major driver in the development of high-risk neuroblastoma, a pediatric cancer with poor prognosis.
|
31444411 |
2019 |
|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYCN-amplified (MNA) neuroblastoma is an aggressive neural crest-derived pediatric cancer.
|
31624245 |
2019 |
|
Malignant Childhood Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Neuroblastoma, a highly malignant childhood tumor of the sympathetic nervous system, is frequently characterized by MYCN gene amplification and high expression of MYCN and c-MYC signature genes.
|
30542116 |
2019 |
|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
By transient overexpression of activated ALK in the transgenic fish overexpressing MYCN, we demonstrate here the cooperation of these two oncogenes in the pathogenesis of a pediatric cancer, neuroblastoma that has resisted most forms of contemporary treatment.
|
25867597 |
2015 |
|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neuroblastoma, a childhood cancer with highly heterogeneous biology and clinical behavior, is characterized by genomic aberrations including amplification of MYCN.
|
26053094 |
2015 |
|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We characterized the mechanistic and translational significance of this finding in neuroblastoma, a childhood cancer with frequent amplification of MYCN.
|
23430699 |
2013 |
|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The studies suggest that use of both the TH-NMYC model of neuroblastoma and the orthotopic xenograft model provide the optimal combination for testing new chemotherapies for this devastating childhood cancer.
|
21559450 |
2011 |
|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of the human MYCN oncogene driven by a tyrosine hydroxylase promoter causes tumours in transgenic mice that recapitulate the childhood cancer neuroblastoma.
|
17449239 |
2007 |
|
Malignant Childhood Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neuroblastoma accounts for 15% of pediatric cancer deaths, and although a few protein-coding genes, such as MYCN, are involved with aggressive pathogenicity, the identification of novel biological targets for therapeutic intervention is still a necessary prerequisite for improving patient survival.
|
17283129 |
2007 |
|
Malignant Childhood Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neuroblastoma is a frequently lethal pediatric cancer in which MYCN genomic amplification is highly correlated with aggressive disease.
|
16822308 |
2006 |
|
Malignant Childhood Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased copy number and overexpression of MYCN in the pediatric cancer rhabdomyosarcoma has been described in a number of small studies with conflicting conclusions about its association with clinicopathologic characteristics.
|
15681534 |
2005 |
|
Malignant Childhood Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the childhood cancer neuroblastoma (NB), the level of expression of the multidrug resistance-associated protein (MRP1) gene is strongly correlated with expression of the MYCN oncogene in primary NB tumors, suggesting that MRP1 may be a target for MYCN-mediated gene regulation.
|
14737110 |
2004 |